After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
The brain-computer interface technology personalizes therapy based on an individual’s brain activity.
Medtronic plc, a Galway-headquartered global leader in healthcare technology, announced the US FDA has approval of BrainSense adaptive Deep Brain Stimulation (aDBS) and BrainSense Electrode Identifier ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...